KPMA calls for more government's R&D investment

Published: 2004-10-21 07:00:00

Updated: 2004-10-21 07:00:00

The Korean government needs to focus on the development of local pharmaceutical industry through substantial R&D investment programs to nurture it as one of the nation's core growth engines, according to data released by the Korea Pharmaceutical Manufacturers Association.

The data showed that ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK